MBCProject_0006_T1_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.660
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V2+0.530
- MYC_TARGETS_V1+0.520
- DNA_REPAIR+0.360
- SPERMATOGENESIS+0.350
- PANCREAS_BETA_CELLS+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.250
- MITOTIC_SPINDLE+0.210
- HEDGEHOG_SIGNALING+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.690
- INTERFERON_GAMMA_RESPONSE-0.630
- IL6_JAK_STAT3_SIGNALING-0.560
- ALLOGRAFT_REJECTION-0.550
- NOTCH_SIGNALING-0.510
- INFLAMMATORY_RESPONSE-0.500
- COMPLEMENT-0.490
- IL2_STAT5_SIGNALING-0.430
- KRAS_SIGNALING_UP-0.430
- TNFA_SIGNALING_VIA_NFKB-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_HB03GSHF | medulloblastoma | — | 0.945 |
| 2 | BS_JZRM1S3T | medulloblastoma | — | 0.944 |
| 3 | BS_AM70R8RG | medulloblastoma | — | 0.942 |
| 4 | BS_S69QZAJR | medulloblastoma | — | 0.941 |
| 5 | BS_W644VEVE | medulloblastoma | — | 0.937 |
| 6 | BS_9NZ2D6AD | medulloblastoma | — | 0.936 |
| 7 | SRR6013537 | — | cohortA3 | 0.935 |
| 8 | BS_GCQFGDTX | medulloblastoma | — | 0.934 |
| 9 | BS_YETBN0RQ | medulloblastoma | — | 0.933 |
| 10 | BS_5VQP0E6K | medulloblastoma | — | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.660 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |